TWIN TRAILBLAZERS SAMAYA AND SAMARA CHAUHAN WALK THE RAMP FOR MENTAL HEALTH & EDUCATIONAL EQUALITY AT DELHI TIMES FASHION WEEK 2025
The sisters are the co-founders of the Policy and Leadership Action Network for Youth (PLAN Y), a youth-led movement that empowers young people to shape policy, advocate for inclusive education, and destigmatize mental health through meaningful, action-oriented change.
Dressed in black as a symbol of resilience and resistance, Samaya and Samara walked not just for themselves, but for the countless others silenced by stigma or circumstance. Their presence was a declaration – young people are not the leaders of tomorrow; they are the change-makers of today.
Samaya Chauhan: Championing Mental Health & Anti-Bullying
Under her initiative, "Project Pause", Samaya has taken a bold stance against bullying and mental health stigma. Her Anti-Bullying Ambassadors Program, now active in over 500 schools, empowers students to lead the charge by identifying, educating, and transforming bullying behaviour- while building peer-support networks that promote safety and empathy.
Samaya has also pioneered Art Therapy Workshops, where young people use graffiti, painting, and other creative forms to process trauma, find their voice, and turn emotional pain into powerful expression. These sessions are now being conducted in both school and university campuses, transforming corridors into spaces of healing and hope.
Samara Chauhan: Bridging the Education Divide
Samara's focus lies in dismantling the barriers to equitable learning. Through her initiative, and webapp, the Learning with Equity and Access Program (LEAP), she is redefining accessibility by creating inclusive digital ecosystems that include learning games, discussion forums, community mentorship, and free study resources – reaching students across socio-economic lines.
Partnering with ATL Sarthi, LEAP has already impacted more than 5,000 students and educators, becoming a scalable model for inclusive education in both urban and rural India.
Beyond the Runway: Action That Resonates
Walking beside children from NGO Pravan, whose lives echo the causes they champion, the sisters displayed a powerful act of solidarity – demonstrating that advocacy is most impactful when grounded in empathy and inclusion.
Their digital movement is equally robust. Through online campaigns, youth forums, and a powerful pledge initiative that has garnered over 40,000 signatures, Samaya and Samara have touched more than 50,000 lives with their message of resilience, equity, and action.
A Runway Reimagined
What unfolded on the runway was far more than a fashion statement. It was a rallying cry – a declaration that youth voices must not only be heard but heeded.
In Samaya and Samara Chauhan, India sees not just young leaders, but a vision of the future in motion – fearless, inclusive, and unstoppable.
About Amity International School
Amity International School, New Delhi, is one of the oldest schools in Delhi NCR, imparting value-based education with a global perspective. It's state-of-the-art facilities and experienced faculty create a nurturing ecosystem where students grow intellectually, emotionally, and socially, preparing them to meet the challenges of the future with confidence and resilience.
Photo - https://mma.prnewswire.com/media/2698916/Amity_Samaya_Samara_Mental_Health.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/twin-trailblazers-samaya-and-samara-chauhan-walk-the-ramp-for-mental-health--educational-equality-at-delhi-times-fashion-week-2025-302468196.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Washington Post
a day ago
- Washington Post
HHS revives child vaccine safety panel sought by anti-vaccine activists
The Department of Health and Human Services announced Thursday it is reviving a long-defunct task force aimed at improving the safety of childhood vaccines, fulfilling a demand of anti-vaccine activists. The resurrection of the panel appears to be the first concrete step to achieve HHS Secretary Robert F. Kennedy Jr.'s longtime goal of upending the current childhood immunization schedule, which recommends which shots children receive and when. The task force will make recommendations focused on developing and refining childhood vaccines that result in 'fewer and less serious adverse reactions,' improving the reporting of adverse reactions and supporting research on vaccine safety, according to HHS. The first report will be sent to Congress within two years. 'By reinstating this Task Force, we are reaffirming our commitment to rigorous science, continuous improvement, and the trust of American families," Jay Bhattacharya, the head of the National Institutes of Health who will lead the task force, said in a statement. 'NIH is proud to lead this effort to advance vaccine safety and support innovation that protects children without compromise." Congress in 1986 mandated the creation of the task force as part of legislation to address childhood vaccine safety. The Task Force on Safer Childhood Vaccines was disbanded in 1998 and released a report that year recommending an expansion of research on vaccine safety and surveillance of injuries. Children's Health Defense, an anti-vaccine group founded by Kennedy, funded a lawsuit filed against Kennedy in May, seeking to compel him to reconvene the task force and submit reports to Congress every two years. Walter Orenstein, a former member of the task force, said reviving the panel isn't necessarily harmful and improvements can still be made to the country's 'really good vaccine safety monitoring system.' But the revamped task force could be a problem if HHS 'constitutes it with people who are extremely biased, who don't have accepted scientific credentials, who have conflicts of interest,' said Orenstein, who led the U.S. immunization program at the Centers for Disease Control and Prevention from 1988 to 2004. Senior leaders from federal health agencies, including the NIH, CDC and Food and Drug Administration, will serve on the task force, according to HHS. Kennedy in June ousted all members of a federal committee of independent vaccine advisers and replaced them with his own appointees, most of whom have criticized coronavirus vaccine policies. Weeks later, that committee announced plans to review the cumulative health effects of the entire childhood vaccination schedule. The schedule includes more than a dozen routine immunizations, many required by states to attend public school, including measles, mumps and rubella, polio and pertussis. Studies have found the cumulative effects of the childhood immunization schedule to be safe. Vaccines undergo rigorous safety testing before they are licensed by the FDA and are continuously monitored for safety once they are in use. While Kennedy said he supports the childhood immunization schedule during his Senate confirmation hearings, he has previously blasted the schedule as 'overburdened' with too many shots and threatening to shorten lives and cause chronic disease. The May lawsuit aiming to re-establish the task force made similar claims that the schedule included too many vaccines and that the increase in vaccine dosage correlates with the rise of autism. Overwhelming scientific evidence demonstrates no link between immunization and autism. Sen. Bill Cassidy (R-Louisiana), a physician who chairs the Senate's health committee, publicly grappled with whether to support Kennedy's nomination. He ultimately voted in favor of Kennedy after securing commitments that the then-nominee would protect federal vaccine oversight. That included a pledge that whoever chairs the health committee would get to choose a representative on any board or commission formed to review vaccine safety. This is a breaking news story and will be updated. Caitlin Gilbert contributed to this report.
